What is ‘Prussian blue insoluble formulations’?

About Prussian blue insoluble formulations:

• It is one of the critical medicines listed by the World Health Organisation for radiological and nuclear emergencies. 
• It was developed under the Technology Development Fund (TDF).
  The drug has been developed based on the technology of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi, a laboratory of the DRDO.
• The formulations are used for the decontamination of Cesium and Thallium.
• The manufacturing and marketing licenses for the commercial use of the drug have been granted to Scott-Edil Pharmacia Limited, Himachal Pradesh, and Skanttr Lifescience, Gujarat, by DCGI.
• The drug will be available under the trade name of Pru-DecorpTM and PruDecorp-MG.

What is the Technology Development Fund (TDF)?

• It has been established to promote self-reliance in defense technology as a part of the 'Make in India' initiative.
• It is a program of the Ministry of Defence executed by DRDO meeting the requirements of Tri-Services, Defence Production, and DRDO. 
• It supports the indigenous development of components, products, systems, and technologies by MSMEs and start-ups.
• Funding:
  • The project cost of up to INR 10 Cr will be considered for funding, subject to a maximum of 90% of the total project cost.
  • The funding will be through the provision of grants to the industry.